Heterocyclic indazole derivatives
View Patent ↗Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R 3 , R 4 and R 5 have the meanings indicated in Claim 1 , are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
1. A compound selected from the following compounds:
No.
Structural formula and/or name
“A1”
“A2”
“A3”
“A4”
“A5”
“A6”
“A7”
“A8”
“A9”
N-(4-Chloro-1H-indazol-5-yl)-N′-[(R)-1-(3-methoxyphenyl)-
ethyl]-1,3,4-oxadiazole-2,5-diamine
“A10”
“A11”
“A12”
“A13”
“A14”
“A15”
“A16”
“A17”
“A18”
“A19”
“A20”
“A21”
“A22”
“A23”
“A24”
“A25”
“A26”
“A27”
“A28”
“A29”
“A30”
“A31”
“A32”
“A33”
“A34”
“A35”
“A36”
“A37”
“A38”
“A39”
“A40”
“A41”
“A42”
“A43”
“A44”
“A45”
or a pharmaceutically usable salt, solvate or stereoisomer thereof, including mixtures thereof in all ratios.
2. A medicaments comprising at least one compound according to claim 1 and optionally excipients and/or adjuvants.
3. A medicaments comprising at least one compound according to claim 1 and at least one further medicament active ingredient.
4. A kit consisting of separate packs of
(a) an effective amount of a compound according to claim 1 and
(b) an effective amount of a further medicament active ingredient.